In its third-quarter 2022 earnings report posted Nov. 3, revenues for Veradigm, Allscripts’ life sciences and payer business, were $145 million compared with $137 million in the previous third quarter.
Three things to know about Allscripts’ outlook for the rest of the year:
- Veradigm’s revenue is expected to grow between 6 percent to 7 percent year over year.
- Veradigm’s adjusted earnings before interest, tax, depreciation and amortization is expected to grow 10 to 15 percent year over year.
- Allscripts expects free cash flow from continuing operations to be between $110 million to $120 million.
